Literature DB >> 16832637

Evaluation of interleukin 13 polymorphisms in systemic sclerosis.

Brigitte Granel1, Christophe Chevillard, Yannick Allanore, Violaine Arnaud, Sandrine Cabantous, Sandrine Marquet, Pierre-Jean Weiller, Jean-Marc Durand, Jean-Robert Harlé, Claire Grange, Yves Frances, Philippe Berbis, Jean Gaudart, Philippe de Micco, André Kahan, Alain Dessein.   

Abstract

Systemic sclerosis (SSc) is a multisystem disease of unknown etiology. It is characterized by excessive cutaneous and visceral fibrosis, damage to small blood vessels, and production of autoantibodies. Interleukin-13 (IL-13) has been shown to be involved in abnormal fibrosis in other diseases. Therefore, we have evaluated its possible involvement in SSc. We analyzed four IL13 gene polymorphisms, rs1800925 (IL13-1055), rs20541 (Arg130Gln), rs847, and rs2243204 in 107 unrelated SSc patients (40 patients having diffuse cutaneous form and 67 patients having limited cutaneous form) and in 170 controls. All subjects were Caucasians. In the total patient population and in the diffuse cutaneous subset, we observed an association between two IL13 polymorphisms, IL13 rs1800925 (IL13-1055), and IL13 rs2243204, and disease (p=0.03-0.04). The IL13 rs2243204T allele was more common in SSc patients (p=0.01, OR=2.3 CI 1.21-4.38) and in the diffuse cutaneous form (p=0.01, OR=2.95, CI 1.35-6.49) than in control subjects. Our result supports the suggestion that polymorphisms in IL13 are associated to SSc and skin fibrosis process. However, further studies on larger and independent population and functional analyses are needed to confirm these findings.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16832637     DOI: 10.1007/s00251-006-0135-0

Source DB:  PubMed          Journal:  Immunogenetics        ISSN: 0093-7711            Impact factor:   2.846


  27 in total

1.  An IL-13 promoter polymorphism associated with increased risk of allergic asthma.

Authors:  T C van der Pouw Kraan; A van Veen; L C Boeije; S A van Tuyl; E R de Groot; S O Stapel; A Bakker; C L Verweij; L A Aarden; J S van der Zee
Journal:  Genes Immun       Date:  1999-09       Impact factor: 2.676

2.  Chronic obstructive pulmonary disease is associated with the -1055 IL-13 promoter polymorphism.

Authors:  T C T M van der Pouw Kraan; M Küçükaycan; A M Bakker; J M C Baggen; J S van der Zee; M A Dentener; E F M Wouters; C L Verweij
Journal:  Genes Immun       Date:  2002-11       Impact factor: 2.676

3.  Production of interleukin 13 by alveolar macrophages from normal and fibrotic lung.

Authors:  A Hancock; L Armstrong; R Gama; A Millar
Journal:  Am J Respir Cell Mol Biol       Date:  1998-01       Impact factor: 6.914

4.  An IL13 coding region variant is associated with a high total serum IgE level and atopic dermatitis in the German multicenter atopy study (MAS-90).

Authors:  X Liu; R Nickel; K Beyer; U Wahn; E Ehrlich; L R Freidhoff; B Björkstén; T H Beaty; S K Huang
Journal:  J Allergy Clin Immunol       Date:  2000-07       Impact factor: 10.793

5.  Preliminary criteria for the classification of systemic sclerosis (scleroderma). Subcommittee for scleroderma criteria of the American Rheumatism Association Diagnostic and Therapeutic Criteria Committee.

Authors: 
Journal:  Arthritis Rheum       Date:  1980-05

6.  IL-4 and IL-13 specifically increase adhesion molecule and inflammatory cytokine expression in human lung fibroblasts.

Authors:  C Doucet; D Brouty-Boyé; C Pottin-Clemenceau; C Jasmin; G W Canonica; B Azzarone
Journal:  Int Immunol       Date:  1998-10       Impact factor: 4.823

7.  The C10/CCL6 chemokine and CCR1 play critical roles in the pathogenesis of IL-13-induced inflammation and remodeling.

Authors:  Bing Ma; Zhou Zhu; Robert J Homer; Craig Gerard; Robert Strieter; Jack A Elias
Journal:  J Immunol       Date:  2004-02-01       Impact factor: 5.422

8.  Interleukin-13 in systemic sclerosis: relationship to nailfold capillaroscopy abnormalities.

Authors:  V Riccieri; T Rinaldi; A Spadaro; R Scrivo; F Ceccarelli; M Di Franco; E Taccari; G Valesini
Journal:  Clin Rheumatol       Date:  2003-05       Impact factor: 2.980

9.  Systemic sclerosis Th2 cells inhibit collagen production by dermal fibroblasts via membrane-associated tumor necrosis factor alpha.

Authors:  Carlo Chizzolini; Yann Parel; Carmelina De Luca; Alan Tyndall; Anita Akesson; Agneta Scheja; Jean-Michel Dayer
Journal:  Arthritis Rheum       Date:  2003-09

10.  Association between an interleukin-13 promoter polymorphism and atopy.

Authors:  T Hummelshoj; U Bodtger; P Datta; H J Malling; A Oturai; L K Poulsen; L P Ryder; P S Sorensen; E Svejgaard; A Svejgaard
Journal:  Eur J Immunogenet       Date:  2003-10
View more
  14 in total

Review 1.  Role of anti-inflammatory cytokines IL-4 and IL-13 in systemic sclerosis.

Authors:  Xiao-Lei Huang; Yu-Jie Wang; Jun-Wei Yan; Ya-Nan Wan; Bing Chen; Bao-Zhu Li; Guo-Jun Yang; Jing Wang
Journal:  Inflamm Res       Date:  2015-03-01       Impact factor: 4.575

2.  Interspecies comparison of human and murine scleroderma reveals IL-13 and CCL2 as disease subset-specific targets.

Authors:  Matthew B Greenblatt; Jennifer L Sargent; Giuseppina Farina; Kelly Tsang; Robert Lafyatis; Laurie H Glimcher; Michael L Whitfield; Antonios O Aliprantis
Journal:  Am J Pathol       Date:  2012-01-11       Impact factor: 4.307

3.  Chitinase 1 is a biomarker for and therapeutic target in scleroderma-associated interstitial lung disease that augments TGF-β1 signaling.

Authors:  Chun Geun Lee; Erica L Herzog; Farida Ahangari; Yang Zhou; Mridu Gulati; Chang-Min Lee; Xueyan Peng; Carol Feghali-Bostwick; Sergio A Jimenez; John Varga; Jack A Elias
Journal:  J Immunol       Date:  2012-07-23       Impact factor: 5.422

4.  Thymic stromal lymphopoietin is up-regulated in the skin of patients with systemic sclerosis and induces profibrotic genes and intracellular signaling that overlap with those induced by interleukin-13 and transforming growth factor β.

Authors:  Romy B Christmann; Allison Mathes; Alsya J Affandi; Cristina Padilla; Banafsheh Nazari; Andreea M Bujor; Giuseppina Stifano; Robert Lafyatis
Journal:  Arthritis Rheum       Date:  2013-05

Review 5.  The immune pathogenesis of scleroderma: context is everything.

Authors:  Matthew B Greenblatt; Antonios O Aliprantis
Journal:  Curr Rheumatol Rep       Date:  2013-01       Impact factor: 4.592

Review 6.  Genetics, Epigenetics, and Genomics of Systemic Sclerosis.

Authors:  Gloria Salazar; Maureen D Mayes
Journal:  Rheum Dis Clin North Am       Date:  2015-05-20       Impact factor: 2.670

7.  Lack of association between interleukin-13 gene polymorphisms (-1055 C/T and +2044 G/A) in Iranian patients with lung cancer.

Authors:  Safoura Sameni; Mohammad Ali Ghayumi; Gholamreza Mortazavi; Zahra Faghih; Mohammad Amin Kashef; Abbas Ghaderi
Journal:  Mol Biol Rep       Date:  2008-05-28       Impact factor: 2.316

8.  Transforming growth factor-β increases interleukin-13 synthesis via GATA-3 transcription factor in T-lymphocytes from patients with systemic sclerosis.

Authors:  Julie Baraut; Dominique Farge; Francette Jean-Louis; Ingrid Masse; Elena Ivan Grigore; Lucas C M Arruda; Jérôme Lamartine; Franck Verrecchia; Laurence Michel
Journal:  Arthritis Res Ther       Date:  2015-07-31       Impact factor: 5.156

9.  Bronchoalveoloar lavage fluid cytokines and chemokines as markers and predictors for the outcome of interstitial lung disease in systemic sclerosis patients.

Authors:  Katrin Schmidt; Lorena Martinez-Gamboa; Susan Meier; Christian Witt; Christian Meisel; Leif G Hanitsch; Mike O Becker; Doerte Huscher; Gerd R Burmester; Gabriela Riemekasten
Journal:  Arthritis Res Ther       Date:  2009-07-17       Impact factor: 5.156

10.  Variants of CTGF are associated with hepatic fibrosis in Chinese, Sudanese, and Brazilians infected with schistosomes.

Authors:  Alain Dessein; Christophe Chevillard; Violaine Arnaud; Xunya Hou; Anas Ahmed Hamdoun; Helia Dessein; Hongbin He; Suzan A Abdelmaboud; Xinsong Luo; Jun Li; Arthur Varoquaux; Adil Mergani; Mohammed Abdelwahed; Jie Zhou; Ahmed Monis; Maira G R Pitta; Nagla Gasmelseed; Sandrine Cabantous; Yaqing Zhao; Aluizio Prata; Carlos Brandt; Nasr Eldin Elwali; Laurent Argiro; Yuesheng Li
Journal:  J Exp Med       Date:  2009-10-12       Impact factor: 14.307

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.